Tom Price, MD, President Trump's pick to head HHS, may have opened the door to a new drug pricing system during his hearing with the Senate finance committee this week, reports Bloomberg.
Supply Chain
President Trump's newest potential pick to head the Food and Drug Administration, Joseph Gulfo, MD, believes agency changes could help reign in high drug costs.
New Brunswick, N.J.-based Johnson & Johnson will acquire Swiss biotechnology company Actelion for $30 billion, reports The New York Times.
Investing time and resources to assess and optimize supplier relationships can greatly benefit an organization, Nigel Crunden, business specialist at Office Depot, wrote in an article for Supply Chain Digital.
Louisville, Colo.-based Global Healthcare Exchange polled 50 supply chain leaders from across the country on their main priorities and outcomes for the healthcare supply chain in 2017.
Advertisement
Deregulation could be the key to lowering high drug costs, said healthcare writer David Hogberg in an op-ed piece for the conservative publication The American Spectator.
Drugmakers and employers are hopeful that the GOP's plan to repeal the ACA will elimninate the Branded Prescription Drug Fee — an excise tax on brand name medications, reports The Hill.
Martin Shkreli, former CEO of Turing Pharmaceuticals, is targeting the drug industry with a new website highlighting the major issues of individual drugmakers, reports STAT News.
The Food and Drug Administration granted priority review designation for Roche's rheumatoid arthritis drug Actemra, reports Reuters.
The Food and Drug Administration recently approved a new indication for the drug Imbruvica.